28% intervention and 24% control discontinued supplement with a minority discontinuing due to adverse events. NPI and ADL were secondary outcomes also reported.īoth trial arms had the same follow‐up and care. Primary outcomes were rate of change in ADAS‐Cog11 and CDR‐SOB, which are both reported in main report. Prospectively registered February 2007, trial started February 2007, completed May 2009.
Medications taken by 20%‐49% of those in the control group: none Medications taken by at least 50% of those in the control group: cholinesterase inhibitor, memantine Smokers: 24.4% intervention, 21.9% control Mean age in years (SD): 76 (9.3) intervention, 76 (7.8) control Individuals with mild to moderate Alzheimer's disease RCT, parallel, (n‐3 DHA vs n‐6 LA), 18 months Alzheimer's Disease Cooperative Study (ADCS)
0 kommentar(er)
